There also does not appear to be an increased risk of serious infections or malignancies with IL-12/IL-23 inhibition; phase 3 trials and real-world studies of ustekinumab have found low rates of serious infections and malignancies [14, 25–27]. This evidence concerns the gene IL37 and infection.